Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and DRG oncology experts’ assumptions.


Related Reports

Malignant Melanoma - Landscape & Forecast - Disease Landscape & Forecast

The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol-Myers Squibb), as well as

View Details

Malignant Melanoma - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (US)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into...

View Details

Malignant Melanoma - Current Treatment - Detailed, Expanded Analysis (US)

Stage of disease, resectability of the primary tumor, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma. BRAF/MEK inhibitor combination r...

View Details

Malignant Melanoma | Disease Landscape and Forecast | G7 | 2019

Although the malignant melanoma market has become increasingly crowded, an evolving trend of combining drug classes to create novel therapies is expanding treatment options for patients. While both...

View Details